The existence of diverging discourses in the media and academia on the use of prescription medications to improve cognition in healthy individuals, i.e. “cognitive enhancement” (CE) creates the need to better understand perspectives from stakeholders. This qualitative focus-group study examined perspectives from students, parents and healthcare providers on CE. Stakeholders expressed ambivalence regarding CE (i.e. reactions to, definitions of, risks, and benefits). They were reluctant to adopt analogies to performance-enhancing steroids and caffeine though these analogies were useful in discussing concepts common to the use of different performance-enhancing substances. Media coverage of CE was criticized for lack of scientific rigor, ethical clarity, and inadvertent promotion of CE. Ambivalence of stakeholders suggests fundamental discomfort with economic and social driving forces of CE. Forms of public dialogue that voice the unease and ambivalence of stakeholders should be pursued to avoid opting hastily for permissive or restrictive health policies for CE.
BabcockQByrneT (2000) Student perceptions of methylphenidate abuse at a public liberal arts college. Journal of American College Health49(3): 143–5.
2.
BarchDMCarterCS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia Research77(1): 43–58.
3.
BergstromLSLynoeN (2008) Enhancing concentration, mood and memory in healthy individuals: An empirical study of attitudes among general practitioners and the general population. Scandinavian Journal of Public Health36(5): 532–7.
BrayCLCahillKSOshierJTPedenCSTheriaqueDWFlotteTRStacpoolePW (2004) Methylphenidate does not improve cognitive function in healthy sleep-deprived young adults. Journal of Investigative Medicine52(3): 192–201.
6.
CaplanAElliottC (2004) Is it ethical to use enhancement technologies to make us better than well?PLoS Medicine1(3): e52.
7.
CaplanALMcHughPR (2007) Shall we enhance? A debate. In GlannonW (ed.) Defining Right and Wrong in Brain Science: Essential Readings in Neuroethics. Washington DC: The Dana Press, 271–301.
8.
CoveneyCMNerlichBMartinP (2008) Modafinil in the media: Metaphors, medicalisation and the body. Social Science & Medicine68(3): 487–95.
9.
DeweyJ (2002/1922) Human Nature and Conduct. New York: Dover Publications.
10.
ElliottRSahakianBJMatthewsKBannerjeaARimmerJRobbinsTW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology131(2): 196–206.
11.
ForliniCRacineE (2009a) Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: Perspectives of a pragmatic study of key stakeholders. Neuroethics2(3): 163–77.
12.
ForliniCRacineE (2009b) Disagreements with implications: Diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics10: 9.
13.
GreelyHSahakianBHarrisJKesslerRCGazzanigaMCampbellPFarahMJ (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature456(7224): 702–5.
14.
HeathCHeathD (2007) Made to Stick: Why Some Ideas Survive and Others Die. New York: Random House.
15.
IllesJBlakemoreCHanssonMGHenschTKLeshnerAMaestreGMagistrettiPQuirionRStrataP (2005) International perspectives on engaging the public in neuroethics. Nature Reviews Neuroscience6(12): 977–82.
16.
IllesJMoserMAMcCormickJBRacineEBlakesleeSCaplanAHaydenECIngramJLohwaterTMcKnightPNicholsonCPhillipsASauveKDSnellEWeissS (2010) Neurotalk: Improving the communication of neuroscience research. Nature Reviews Neuroscience11(1): 61–9.
17.
JonsenAR (1991) Casuistry as methodology in clinical ethics. Theoretical Medicine12(4): 295–307.
18.
LakoffGJohnsonM (1980) Metaphors We Live By. Chicago: University of Chicago Press.
19.
LauranceJ (2003) Abuse hits students looking for an exam kick. The Independent, 26August, p. 5.
20.
LeshnerAI (2004) Ethical issues in taking neuroscience research from bench to bedside. Cerebrum6(4): 66–72.
21.
MehtaMAOwenAMSahakianBJMavaddatNPickardJDRobbinsTW (2000) Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. Journal of Neuroscience20(6): RC65.
22.
MorencyK (2006) More students abusing ritalin as study aid. Montreal Gazette, 8January, p. A3.
23.
Nature. (2007) Enhancing, not cheating. Nature450(7168): 320.
24.
Oxford English Dictionary. (1989) Ambivalence, n. In OED Online (2nd edition). Oxford: Oxford University Press. Available at: dictionary.oed.com/cgi/entry/50006963.
25.
ParensE (2005) Authenticity and ambivalence: Toward understanding the enhancement debate. Hastings Center Report35(3): 34–41.
26.
ParensE (2006) Creativity, gratitude, and the enhancement debate. In IllesJ (ed.) Neuroethics: Defining the Issues in Theory, Practice and Policy. Oxford: Oxford University Press, 75–86.
27.
President’s Council on Bioethics. (2003) Beyond Therapy. Washington, DC: President’s Council on Bioethics/Harper Collins.
28.
RacineE (2010) Pragmatic Neuroethics: Improving Treatment and Understanding of the Mind-Brain. Cambridge, MA: MIT Press.
29.
RacineE (forthcoming) Neuroscience and the media: Ethical challenges and opportunities. In IllesJSahakianB (eds) Oxford Handbook of Neuroethics. Oxford: Oxford University Press.
30.
RacineEForliniC (2009) Expectations regarding cognitive enhancement create substantial challenges. Journal of Medical Ethics35(8): 469–70.
31.
RacineEForliniC (2010) Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Ethical blindspots in current debates. Neuroethics3(1): 1–14.
32.
RacineEBar-IlanOIllesJ (2005) fMRI in the public eye. Nature Reviews Neuroscience6(2): 159–64.
33.
RossS (2006) Students turn to smart drugs for exam help. The Scotsman, 2June, p. 7.
34.
SabiniJMonterossoJ (2005) Judgments of the fairness of using performance enhancing drugs. Ethics & Behavior15(1): 81–94.
35.
SandelMJ (2004) The case against perfection: What’s wrong with designer children, bionic athletes, and genetic engineering. Atlantic Monthly292(3): 51–62.
36.
SavulescuJ (2006) Justice, fairness, and enhancement. Annals of the New York Academy of Sciences1093: 321–38.
37.
WhiteBPBecker-BleaseKAGrace-BishopK (2006) Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health54(5): 261–8.
38.
WilensTEAdlerLAAdamsJSgambatiSRotrosenJSawtelleRUtzingerLFusilloS (2008) Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry47(1): 21-31.
39.
WilliamsSJSealeCBodenSLowePSteinbergDL (2008) Waking up to sleepiness: Modafinil, the media and the pharmaceuticalisation of everyday/night life. Sociology of Health & Illness30(6): 839–55.
40.
ZernikeK (2005) The difference between steroids and ritalin is …The New York Times, 20March, p. 3.
